APA (7th ed.) Citation

AB, O., L, G., DM, O., JW, K., G, G., V, S., . . . D, L. (2025). Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): An open-label, randomised, controlled, phase 3 trial. Lancet (London, England), 405(10496), 2205. https://doi.org/10.1016/S0140-6736(25)01040-2

Chicago Style (17th ed.) Citation

AB, Olawaiye, et al. "Relacorilant and Nab-paclitaxel in Patients with Platinum-resistant Ovarian Cancer (ROSELLA): An Open-label, Randomised, Controlled, Phase 3 Trial." Lancet (London, England) 405, no. 10496 (2025): 2205. https://doi.org/10.1016/S0140-6736(25)01040-2.

MLA (9th ed.) Citation

AB, Olawaiye, et al. "Relacorilant and Nab-paclitaxel in Patients with Platinum-resistant Ovarian Cancer (ROSELLA): An Open-label, Randomised, Controlled, Phase 3 Trial." Lancet (London, England), vol. 405, no. 10496, 2025, p. 2205, https://doi.org/10.1016/S0140-6736(25)01040-2.